Clinical analysis of Paclitaxel and Platinum in Recurrent Carcinoma of the Uterine Cervix / 대한산부인과학회지
Korean Journal of Obstetrics and Gynecology
; : 1448-1455, 2005.
Artigo
em Coreano
| WPRIM (Pacífico Ocidental)
| ID: wpr-14107
Biblioteca responsável:
WPRO
ABSTRACT
OBJECTIVE:
This study was performed to evaluate the efficacy and the toxicity of paclitaxel and platinum in patients with recurrent cervical carcinoma.METHODS:
Twenty nine patients were treated with paclitaxel 135-175 mg/m2 and cisplatin 50-75 mg/m2 or carboplatin at AUC 5 every 3 weeks for a maximum of six courses from January 2001 to January 2004.RESULTS:
A total 134 cycles with paclitaxel and platinum were administered. Ten patients (34.2%) achieved an objective response, including four complete responses (13.6%) and six partial responses (20.6%). Overall survival was 13.2 months, and the response and non-response group were 23.2 and 8.1 months, respectively (p=0.01). Clinical response according to recurrent site was significantly different (p=0.048) but, survival was not (p=0.22). Grade 3 or 4 granulocytopenia in 75.9% of patients was developed and one expired due to neutropenic sepsis after first cycle chemotherapy.CONCLUSION:
The combination of paclitaxel and platinum seems relatively well tolerated and has 34.2% response rate in patients with recurrent cervical cancer. Further study for this combination chemotherapy and prognostic factor should be needed.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Platina
/
Neoplasias do Colo do Útero
/
Colo do Útero
/
Carboplatina
/
Cisplatino
/
Paclitaxel
/
Sepse
/
Área Sob a Curva
/
Agranulocitose
/
Tratamento Farmacológico
Tipo de estudo:
Estudo prognóstico
Limite:
Feminino
/
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Obstetrics and Gynecology
Ano de publicação:
2005
Tipo de documento:
Artigo